Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference183 articles.
1. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice;Gahr;Br J Cancer,2013
2. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J Thorac Oncol,2014
3. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018
4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011
5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009
Cited by 92 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen;Lung Cancer;2024-09
2. Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study;BMC Cancer;2024-08-14
3. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis;The Lancet Oncology;2024-08
4. Research trends in lung cancer and the tumor microenvironment: a bibliometric analysis of studies published from 2014 to 2023;Frontiers in Oncology;2024-07-31
5. Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions;Journal of Clinical Medicine;2024-07-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3